Skip to main content

Table 4 Major molecular response at 12 months

From: The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis

Intervention

Mean

95%LCrI

95%UCrI

Probability of response

Imatinib 400 mg daily

33.6%

Reference category

Dasatinib 100 mg daily

51.1%

43.9%

58.5%

Nilotinib 300 mg twice daily

58.7%

49.6%

67.5%

Nilotinib 400 mg twice daily

57.8%

48.7%

66.8%

Imatinib 800 mg daily

48.1%

43.1%

53.1%

Response Odds Ratios

Imatinib 400 mg daily

N/A

Reference category

Dasatinib 100 mg daily

2.09

1.55

2.78

Nilotinib 300 mg twice daily

2.87

1.95

4.11

Nilotinib 400 mg twice daily

2.76

1.88

3.98

Imatinib 800 mg daily

1.84

1.50

2.24

  1. LCrI: Lower boundary of derived credible interval; UCrI: Upper foundry of derived credible interval.